Cetuximab‐based therapy <i>vs</i> noncetuximab therapy in advanced or metastatic colorectal cancer: a meta‐analysis of seven randomized controlled trials

Liu, L.; Cao, Yukun; Tan, Angelina D.; Liao, Cun; Gao, Fei

doi:10.1111/j.1463-1318.2009.01916.x

Cited by 7 publications

(4 citation statements)

References 44 publications

(68 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Cetuximab was chosen because it is in use for the treatment of certain types of human cancers (33,40), and thus the study could have clinical implications. Compared with untreated controls, cetuximab raised the BP of mice on normal salt diets by 25 mm Hg (120 Ϯ 3 versus 145 Ϯ 2 mm Hg) and that of those on high salt diets by 34 mm Hg (127 Ϯ 3 versus 161 Ϯ 6 mm Hg) (Fig.…”

Section: Resultsmentioning

confidence: 99%

Epoxyeicosatrienoic Acids (EETs) Regulate Epithelial Sodium Channel Activity by Extracellular Signal-regulated Kinase 1/2 (ERK1/2)-mediated Phosphorylation

Pidkovka

Rao

Mei

et al. 2013

Journal of Biological Chemistry

View full text Add to dashboard Cite

Background:The epoxygenase metabolites (EETs) inhibit ENaC by unknown mechanisms. Results: 14,15-EET stimulates an ERK1/2-catalyzed inhibitory phosphorylation of the ENaC ␤ and ␥ subunits. Conclusion: A CYP2C44 epoxygenase/ERK1/2-mediated pathway for ENaC regulation has been characterized. Significance: Roles for human CYP2C8 and CYP2C9 as antihypertensive epoxygenases and for the EETs as antihypertensive drug targets are proposed.

show abstract

Section: Resultsmentioning

confidence: 99%

Epoxyeicosatrienoic Acids (EETs) Regulate Epithelial Sodium Channel Activity by Extracellular Signal-regulated Kinase 1/2 (ERK1/2)-mediated Phosphorylation

Pidkovka

Rao

Mei

et al. 2013

Journal of Biological Chemistry

View full text Add to dashboard Cite

show abstract

“…Many previous studies have confirmed the positive effect of rash on the prediction of treatment outcome and survival of patients treated with EGFR inhibitors [ 13 , 20 – 22 , 41 ]. In this study, a relationship between degree of rash and response to treatment was found ( p = 0.058; n = 49), but it was not statistically significant.…”

Section: Discussionmentioning

confidence: 85%

CA-SSR1 Polymorphism in Intron 1 of the EGFR Gene in Patients with Malignant Tumors Who Develop Acneiform Rash Associated with the Use of Cetuximab

et al. 2015

View full text Add to dashboard Cite

Background and ObjectiveEpidermal growth factor receptor (EGFR) inhibitors are not equally effective in all cancer patients. One potential clinical factor that could help in selecting patients who may benefit from treatment with cetuximab is acneiform rash, which correlates with the clinical response to EGFR inhibitors. Some previous studies have suggested that the tendency to develop rash may depend on polymorphisms in the EGFR gene. In this investigation, the association of degree of CA dinucleotide polymorphism with skin rash and cetuximab therapy outcome was examined.MethodsThe study included 60 patients treated with cetuximab. For each patient, the severity of acneiform rash was assessed, and the type of polymorphism was determined by genotyping. Associations between genotypes, the acneiform rash, and response to treatment were determined by using the chi-square test and Spearman’s rank correlation. The cutoffs S ≤ 17(CA), L > 17(CA), n(CA) ≤ 35, and n(CA) > 35 were tested, as well as the sum of the two allele repetitions.ResultsA correlation was found between body surface area covered by rash and the sum of the two allele repetitions (p = 0.030). No statistically significant relationship between genotype and response to treatment was observed. However, in patients who have had partial remission, we noticed a higher incidence of polymorphism, with less CA dinucleotide repetitions and early onset of rash.ConclusionA correlation between genotype and severity of rash was observed. That is, the severity of rash decreased with an increased number of CA repetitions.

show abstract

“…A meta-analysis of seven randomized controlled clinical trials showed that cetuximab and chemotherapy improves OS, PFS, and response rates compared to chemotherapy alone. However, in this meta-analysis cetuximab-related effect was not adjusted for the K-ras tumor status [42].…”

Section: Correlation Between Kras Mutation Status and Prognosismentioning

confidence: 95%

Frequency and Clinical Impact of KRAS Mutations in Patients with Colorectal Cancer from the Middle East

Zekri

Karim²,

Alshehri

et al. 2016

J. Anal. Oncol.

View full text Add to dashboard Cite

Background: Colorectal cancer (CRC) is a significant healthcare burden worldwide and in the Middle East (ME). KRAS mutation confers resistance to epidermal growth factor receptor (EGFR) inhibitors in the treatment of advanced CRC. Data regarding the rate of KRAS mutation from the ME are scattered and scarce. We aim to collect and review all sizable studies evaluating the frequency of KRAS mutations in CRC patients from the ME. Method:A Pubmed and Google Scholar search was conducted using keywords including KRAS, K-ras, colorectal cancer and Middle East, along with names of each ME country. Studies including over 90 patients were included in the review.Result: Eleven studies containing more than 90 patients were identified. Among all eleven studies, KRAS mutation rate ranged from 13 to 56%. Five studies reported KRAS mutation rate in M1 stage either exclusively or as part of subgroup analysis. In these studies, mutations were found in 8-45% of cases. KRAS mutations were associated with female gender, M1 stage and high CEA in 3, 2, and 1 studies respectively. Conclusion:There is a broad range of variability in KRAS mutation rate reported in different studies from the ME. This may have been due to small number of patients in the studies and lack of centralized testing for KRAS mutations. Larger and more coordinated studies from the ME population are required to ascertain the accuracy of KRAS mutation rate.

show abstract

Cetuximab‐based therapy vs noncetuximab therapy in advanced or metastatic colorectal cancer: a meta‐analysis of seven randomized controlled trials

Abstract: Cetuximab-based therapy improves PFS and OS resulting in better ORR vs noncetuximab therapy. Its most common and severe AE is skin toxicity that should be predictable and manageable.

Cited by 7 publications

References 44 publications

Epoxyeicosatrienoic Acids (EETs) Regulate Epithelial Sodium Channel Activity by Extracellular Signal-regulated Kinase 1/2 (ERK1/2)-mediated Phosphorylation

Epoxyeicosatrienoic Acids (EETs) Regulate Epithelial Sodium Channel Activity by Extracellular Signal-regulated Kinase 1/2 (ERK1/2)-mediated Phosphorylation

CA-SSR1 Polymorphism in Intron 1 of the EGFR Gene in Patients with Malignant Tumors Who Develop Acneiform Rash Associated with the Use of Cetuximab

Frequency and Clinical Impact of KRAS Mutations in Patients with Colorectal Cancer from the Middle East

Contact Info

Product

Resources

About